Effect of switching to teneligliptin from other dipeptidyl peptidase‐4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease

Effect of switching to teneligliptin from other dipeptidyl peptidase‐4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease

Abstract Aims/Introduction The objective of the present study was to elucidate the effect of switching to teneligliptin from other dipeptidyl peptidase‐4 (DPP‐4) inhibitors on glucose control and renoprotection in type 2 diabetes mellitus patients with diabetic kidney disease. Materials and Methods...

Full description

Bibliographic Details
Main Authors:	Munehiro Kitada, Yoshio Ogura, Kyoko Nitta, Mizue Fujii, Keizo Kanasaki, Kazunori Konishi, Yasuo Iida, Atsushi Nakagawa, Daisuke Koya
Format:	Article
Language:	English
Published:	Wiley 2019-05-01
Series:	Journal of Diabetes Investigation
Subjects:	Diabetic kidney disease Plasma DPP‐4 activity Teneligliptin
Online Access:	https://doi.org/10.1111/jdi.12917

Similar Items

Teneligliptin in management of type 2 diabetes mellitus
by: Sharma SK, et al.
Published: (2016-08-01)

Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study)
by: Ghosh S, et al.
Published: (2016-11-01)

The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice
by: Takayasu Ideta, et al.
Published: (2015-12-01)

Renoprotective effects of teneligliptin: An observational study
by: Prabhat Agrawal, et al.
Published: (2021-01-01)

Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis
by: Takahiro Ozutsumi, et al.
Published: (2020-03-01)

Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
by: Han E, et al.
Published: (2020-11-01)

Teneligliptin-induced hair loss: A case report
by: Prabhat K Agrawal, et al.
Published: (2020-01-01)

Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus
by: Yayoi Nishida, et al.
Published: (2020-04-01)

A pharmacoeconomic analysis to compare cost-effectiveness of metformin plus teneligliptin with metformin plus glimepiride in patients of type-2 diabetes mellitus
by: Tanya Tandon, et al.
Published: (2019-01-01)

Effects of teneligliptin on PDMPs and PAI-1 in patients with diabetes on hemodialysis
by: Okuda Y, et al.
Published: (2016-04-01)

Efficacy and Safety of Teneligliptin in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Xiaoxuan Li, et al.
Published: (2018-05-01)

QT/QTc safety and efficacy evaluation of teneligliptin in Indian type 2 diabetes mellitus patients: the “thorough QT/QTc” study (Q-SET study)
by: Erande S, et al.
Published: (2019-06-01)

Deficiency in Dipeptidyl Peptidase-4 Promotes Chemoresistance Through the CXCL12/CXCR4/mTOR/TGFβ Signaling Pathway in Breast Cancer Cells
by: Shaolan Li, et al.
Published: (2020-01-01)

Renoprotective Effect of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, in Streptozotocin-Induced Type 1 Diabetic Mice
by: Gwon-Soo Jung, et al.
Published: (2016-03-01)

The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats
by: Takahiro Oguma, et al.
Published: (2015-04-01)

Efficacy and safety of teneligliptin in Indian patients with inadequately controlled Type 2 diabetes mellitus: A randomized, double-blind study
by: Piyush Agarwal, et al.
Published: (2018-01-01)

Influence of FMO3 and CYP3A4 Polymorphisms on the Pharmacokinetics of Teneligliptin in Humans
by: Jin-Woo Park, et al.
Published: (2021-08-01)

Association between Dipeptidyl Peptidase-4 Inhibitors and Allergic Rhinitis in Asian Patients with Diabetes
by: Hsin-Hung Chen, et al.
Published: (2019-04-01)

Teneligliptin protects against hypoxia/reoxygenation-induced endothelial cell injury
by: Zhen Zhang, et al.
Published: (2019-01-01)

Dipeptidyl-Peptidase-IV Inhibitors, Imigliptin and Alogliptin, Improve Beta-Cell Function in Type 2 Diabetes
by: Xu Liu, et al.
Published: (2021-09-01)

Micro-Environmental Signature of The Interactions between Druggable Target Protein, Dipeptidyl Peptidase-IV, and Anti-Diabetic Drugs
by: Chiranjib Chakraborty, et al.
Published: (2017-01-01)

Screening for Potential Novel Probiotics With Dipeptidyl Peptidase IV-Inhibiting Activity for Type 2 Diabetes Attenuation in vitro and in vivo
by: Fenfen Yan, et al.
Published: (2020-01-01)

Association between the Use of Dipeptidyl Peptidase 4 Inhibitors and the Risk of Dementia among Patients with Type 2 Diabetes in Taiwan
by: Kuan-Chan Chen, et al.
Published: (2020-02-01)

Initial investigation of efficacy and safety of a new dipeptidyl peptidase-4 inhibitor, gosogliptin, for type 2 diabetes in Russia
by: Lyudmila Viktorovna Nedosugova, et al.
Published: (2014-10-01)

DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS
by: Erna Kristin
Published: (2016-12-01)

Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy in elderly type 2 diabetes patients in Thailand
by: Permsuwan U, et al.
Published: (2016-09-01)

Effect of dipeptidyl peptidase 4 inhibitors on cardiovascular events in type-2 diabetes patients with renal impairment: A systematic review and meta-analysis
by: Maneesha Khalse, et al.
Published: (2020-01-01)

UNEXPECTED ADVERSE REACTIONS OF THE DRUGS OF THE GROUP OF INHIBITORS OF DIPEPTIDYL PEPTIDASE-4
by: T. V. Romanova, et al.
Published: (2018-06-01)

Relevance of Autophagy Induction by Gastrointestinal Hormones: Focus on the Incretin-Based Drug Target and Glucagon
by: Keizo Kanasaki, et al.
Published: (2019-05-01)

CD26/DPP-4: Type 2 Diabetes Drug Target with Potential Influence on Cancer Biology
by: Emi Kawakita, et al.
Published: (2021-05-01)

Meat Proteins as Dipeptidyl Peptidase IV Inhibitors and Glucose Uptake Stimulating Peptides for the Management of a Type 2 Diabetes Mellitus In Silico Study
by: Paulina Kęska, et al.
Published: (2019-10-01)

Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid
by: Kaisa Tasanen, et al.
Published: (2019-06-01)

Combination treatment for type 2 diabetes mellitus (T2DM) : dipeptidyl peptidase-4 inhibitors (DPP-4) and metformin
by: Erna Kristin
Published: (2017-10-01)

Renoprotective Effects of DPP-4 Inhibitors
by: Daiji Kawanami, et al.
Published: (2021-02-01)

Discovery of Potential Natural Dipeptidyl Peptidase-4 Inhibitors for Type-2 Diabetes Treatment via Structure-Based Virtual Screening
by: Sara Ranjbar, et al.
Published: (2019-09-01)

Identification of Dipeptidyl Peptidase (DPP) Family Genes in Clinical Breast Cancer Patients via an Integrated Bioinformatics Approach
by: Tak-Kee Choy, et al.
Published: (2021-07-01)

Evaluation of Hypoglycaemic Effects of Dipeptidyl Peptidase–4 Inhibitors and Biguanide on Type-2 Diabetic subjects: A six months trial
by: Naghma Ms., et al.
Published: (2020-12-01)

The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial
by: Frederich Robert, et al.
Published: (2012-07-01)

Increased Plasma Dipeptidyl Peptidase-4 (DPP4) Activity Is an Obesity-Independent Parameter for Glycemic Deregulation in Type 2 Diabetes Patients
by: Jit Sarkar, et al.
Published: (2019-07-01)

Renoprotective Effect of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus
by: Hiroki Esaki, et al.
Published: (2017-11-01)